Authors
Valentin Butnari, Deepak Kumar Dinkar, Jayan Dewantha Jayasinghe, Manthan Patel, Nirooshun Rajendran, Sherif Raouf, Madapura Marulasiddappa Pradeepa, Mohamed Adhnan Thaha
Published in
Biomarker insights. Volume 21. Pages 11772719261478092. Epub Sep 25, 2026.
Abstract
Colorectal cancer (CRC) represents a significant global health concern, ranking as the third most diagnosed cancer and the second leading cause of cancer deaths in the UK. Although population-based bowel cancer screening programs (BCSP) facilitate early diagnosis, uptake remains variable. Blood-based biomarkers, such as human progastrin 80 (hPG80), offer a patient-friendly approach to enhance screening compliance and clinical management. This scoping review, conducted according to PRISMA-ScR guidelines and registered in PROSPERO (CRD420250654595), searched Ovid Medline/PubMed, Ovid Embase, and Cochrane databases from January 1990 to January 2025. Studies assessing plasma hPG80 as a CRC biomarker were included, while reviews, in vitro studies, and animal models were excluded. Quality assessment was performed using the Newcastle-Ottawa Scale, and findings were synthesized narratively. Five articles encompassing 2,692 participants met the inclusion criteria. The included studies consistently demonstrated significant overexpression of hPG80 in CRC patients compared to non-cancer controls, with an increased median progastrin concentration in the CRC group (27.5 pmol/L) compared to patients with polyps or normal controls. Furthermore, hPG80 levels decreased significantly post-surgery (from 272.3 ± 12.0 pmol/L to 161.3 ± 11.0 pmol/L), reflecting its sensitivity to tumor burden and potential for treatment monitoring. Methodologically, literature has shifted from early radioimmunoassays to safer, cost-effective enzyme-linked immunosorbent assays (ELISA). A meta-analysis was not feasible due to variations in analytes, assays, populations, thresholds, and a lack of CRC-specific sensitivity, specificity, or area under the curve data. This review highlights hPG80's promise as a reliable, reproducible blood-based biomarker for CRC integration into BCSPs and symptomatic pathways. However, optimal thresholds, stage-specific correlation, molecular subtypes, and cost-effectiveness remain unanswered. The ongoing MOTION trial (NCT07035691) is currently evaluating hPG80's performance within UK symptomatic suspected colorectal cancer referral pathways.
PMID:
43034424
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0